Recruiting
Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer
About this study
Based on the unique patented MONOD and Methyl Titan methylation sequencing technology on lung cancer tissue and blood samples, a lung cancer MRD monitoring panel is designed. The panel is used to detect molecular residual disease of stage IB-IIIB non-small cell lung cancer patients underwent radical surgery, explore personalized analysis models, and conduct research on recurrence monitoring for non-small cell lung cancer patients.
- Condition
- Non-small Cell Lung Cancer
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not stated
Inclusion 8
- Minimum age: 18 years
- Study condition: Non-small Cell Lung Cancer
- Age ≥ 18 years old, regardless of gender;
- Patients with pathological diagnosis of non-small cell lung cancer and clinical staging of stage IB-IIIB;
- Able to undergo radical surgical treatment;
- Physical condition score (ECOG) ≤1;
- The expected survival time exceeds 24 months;
- Volunteer to participate in this study and sign an informed consent form.
Exclusion 9
- Individuals with a history of other malignant tumors within 5 years;
- Those who have undergone neoadjuvant therapy before surgery;
- Postoperative incision margin R1 or incision margin R2;
- Those who have undergone a blood transfusion within 2 weeks before the surgery;
- Individuals with systemic inflammatory response syndrome;
- Those with serious diseases of important organs such as the heart, lungs, kidneys, and brain;
- Participants in other clinical trials within the past 30 days and have taken investigational drugs;
- Due to various reasons, sampling cannot be completed, samples do not meet the requirements, or baseline samples (preoperative and postoperative plasma samples, tumor tissue samples) are incomplete;
- Researchers believe that it is not appropriate to participate in this experiment.
Where
1 site, 1 recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Potential match only. Final eligibility is determined by the study team.